Since the launch of the entrepreneurial and investment boom in the Internet medical and health field in 2014, it has been more than two years now. Obviously, after a period of "wind-flight flight", the capital boom returned to rationality, and most of the companies that had settled down were companies with obvious competitive advantages and certain favorable models. According to statistics on medical investment, most of the projects that entered the late stage (C round and above) entered the medical field before 2010. This shows that the "Internet +" that entered the large-scale medical service seems to be the biggest incentive for setting up medical fever in recent years. However, the foundation for Internet medical companies to do a good job is to continue to accumulate rather than rely on the heat of the moment.
Despite the slowdown in the industry, according to data from the Arterial Eggshell Research Institute, in 2016, the digital medical industry sold a total of 261 transactions, with total investment and financing exceeding US$2.6 billion. This year's level ranked second in 2011. From this perspective, the status quo of the medical industry is obviously far from the description of "cold winter". Some start-up medical companies feel the pressure of financing and grain-cutting. It is actually the role of the market's metabolic mechanism: since 2014, the number of new medical startups has exploded, and the business repetition rate has increased; while the total amount of funds flowing into the industry has not kept up. The proportion of companies that have received financing has naturally decreased. Looking at some major financing events, such as Ping An’s doctors set a $500 million A round of the largest Internet financing startup’s single largest financing record, nearly $1 billion in carbon cloud intelligence in the medical big data field, and 500 million yuan in the genetic field. The number of single financings obtained by some companies that are welcomed by capital is almost no increase. Summarizing the status quo of medical venture capital investment is: more start-up companies, increased total financing, and more uneven investment.
.jpg)
A further interpretation of this phenomenon is that the medical industry is becoming more and more crowded, but the market is more ruthless for those who are not suitable. What everyone feels is the magnified survival of the fittest. The winter is the winter of the laggards. Excellent people can get more financing and live better, and find profitability earlier; others are behind some people because of some shortcomings. If they encounter problems with financing, the possibility of decline will increase.
Next, medical entrepreneurs will face more medical opportunities arising from the gradual liberalization of policies, and will also encounter more intense competition. According to the database of the Arterial Network Eggshell Institute, as the concept of Internet medical care is not yet mature, the largest proportion in this field is the A round and the previous company. Then, under the above-mentioned medical investment atmosphere, what are the advantages that make these companies stand out, and what problems may cause them to be restricted? Here, we summarize some of the highlights from this group of medical companies in the early stage of the venture, and analyze the major challenges they face.
Highlight 1: The use of health big data
The concept of health big data is beginning to be popular in the medical field. This is one of the biggest achievements of Internet + health. Because health itself is an industry that attaches great importance to effective data and wastes a lot of data, and data from people themselves will eventually Be a valuable asset for health management – ​​provide “tailor-made†health behavior advice by collecting personal and daily health behaviors and other specific indicators, and choose preventive interventions when necessary.
In the startup mobile health enterprise, the personalized health management platform pays more attention to the collection and processing of personal information. For example, the platform such as “Miao Health†allows users to access relevant data to complete user data access by means of docking intelligent hardware, physical examination and online health assessment. Access to data through a professional medical team and consultant team, combined with big data algorithms and user personalized data analysis, to develop a personalized health behavior intervention program. These programs use the mission mechanism and reward system to urge users to improve their health behaviors, thereby achieving the goal of improving health.
When information collection, data analysis, solutions, health interventions, and value-added services are integrated, users can feel a more detailed mobile health management experience.
The quality of raw materials for health care products should be taken seriously, including the production process, raw materials, and production technology of health care products, all of which must be strictly controlled. When selecting raw material suppliers, health care product manufacturers should Equipment and product quality are strictly inspected and investigated to avoid problems. Our Xi'an Hengruikang Biotechnology Co., Ltd. has been established for 20 years, specializing in the production and supply of raw materials, and has relevant qualifications and supporting facilities. Sound production equipment and professional production personnel. Our main products are: Improve Immunity ,Healthcare Product,Sex Enhancement Powder, Loss Weight ,Anti-hair Loss Powder,Immunity enhancement, Develop immunity ,Strong immune system.
Healthcare Products,Meloxicam Powder,Anti-Hair Loss Minoxidil Powder,Tetracaine Ophthalmic Solution
Xi'an Henrikang Biotech Co.,Ltd , https://www.xianhenrikangbio.com